From: CT Department of Public Health <noreply-dphimmunizations@ct.gov>

Sent: Friday, April 23, 2021 8:27 PM

Subject: J&J Pause Lifted Following Safety Review





Dear Connecticut COVID Vaccine Providers,

This evening, the FDA and CDC recommended lifting the pause on administration of the J&J vaccine, following a safety review and the recommendation of the ACIP.

Connecticut COVID Vaccine providers may now resume administration of the J&J vaccine upon reviewing the <u>statement from the FDA and CDC</u>, the updated <u>provider fact sheet</u>, and updating the <u>recipient fact sheet</u> furnished to patients.

The key points of the FDA and CDC statement are as follows:

- Use of the Janssen COVID-19 Vaccine should be resumed in the United States.
- The FDA and CDC have confidence that this vaccine is safe and effective in preventing COVID-19.
- The FDA has determined that the available data show that the vaccine's known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.
- At this time, the available data suggest that the chance of TTS occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.

Additional information for Connecticut COVID Vaccine Providers:

- Providers can resume use of J&J that is in inventory at this time
- J&J will be made available for ordering by COVID vaccine providers in the next week
 providers may place orders for J&J in their order that is due this Tuesday for orders that will arrive on May 3
- Providers who have a specific need for earlier shipment of J&J vaccine should email Sam.Kruse@ct.gov and Patricia.Firmender@ct.gov. Not all requests will be able to be accommodated
- As a reminder, the type of vaccine offered should be transparent to the individual at the time of scheduling

- Vaccine confidence is a high priority as we continue our effort to ensure access for all
 Connecticut residents and continue to increase vaccine coverage across the State.
 Our collective efforts to reassure individuals of the safety of vaccines and the
 protection they afford is more important than ever
- Providers can continue to order whichever vaccine they determine to be most suitable for the clinical models they are using and which they think will be best received by their patients
- There will be a COCA call for clinicians on Tuesday at 2pm: Information is here.
- As a reminder, all CoVP providers are required to report adverse events to the Vaccine Adverse Event Reporting System (VAERS). VAERS is a passive data collection system that accepts reports from any patient or provider regarding confirmed and potential adverse events relating to vaccination: https://vaers.hhs.gov/.

In addition, we wanted to share the following programmatic updates:

- The FEMA mobile unit will continue to operate with Pfizer for the foreseeable future
- DPH's mobile units will continue to operate with mRNA vaccines for the foreseeable future.

Thank you for everything that you are doing to provide COVID vaccines.

Department of Public Health 410 Capitol Ave. Hartford, CT 06134

Phone Number: 860-509-8000

You are receiving this email because you opted in to updates from the Connecticut Department of Public Health.



Preferences | Unsubscribe